Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.

Clinical genitourinary cancer - 1 Aug 2026

Wei Nancy, O'Byrne Jamie J, Muniz Miguel, Rhodes Lauren, Haloi Rimki, Nikanpour Yalda, Hashemi Milad Bonakdar, Ahmed Eman E, Kwon Eugene D, Childs Daniel S, Andrews Jack R

Abstract excerpt

BACKGROUND: Circulating tumor DNA (ctDNA) genomic testing is increasingly used in advanced prostate cancer (aPC) to identify actionable alterations, however the longitudinal nature of tumor mutation burden (TMB) remains poorly characterized. Current guidelines recommend somatic testing at diagnosis of metastatic hormone-sensitive or castration-resistant disease, but do not address serial testing. While prior...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to Biomarkers, Tumor

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Circulating Tumor DNA

Share to Longitudinal Studies

Share to Mutation

Share to Prostatic Neoplasms

Source

Identifiers

PMID: 42331681
DOI: 10.1016/j.clgc.2026.102591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Longitudinal Tumor Mutation Burden Dynamics in Advanced Prostate Cancer Using Circulating Tumor DNA Profiling.PMID 42331681Read ↗

Circulating Tumor DNA Analysis on Metastatic Prostate Cancer with Disease ProgressionSemantic proximity Read ↗

Clinical and genomic insights into circulating tumor DNA-based alterations across the spectrum of metastatic hormone-sensitive and castrate-resistant prostate cancer.Semantic proximity Read ↗

Repeat Next-Generation Sequencing Testing on Progression in Men With Metastatic Prostate Cancer Can Identify New Actionable AlterationsSemantic proximity Read ↗

Genomic Analysis of Circulating Tumor DNA in 3,334 Patients with Advanced Prostate Cancer Identifies Targetable BRCA Alterations and AR Resistance Mechanisms.Semantic proximity Read ↗

Concordance of Circulating Tumor DNA and Matched Metastatic Tissue Biopsy in Prostate Cancer.Semantic proximity Read ↗

Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial TherapySemantic proximity Read ↗

Clinical and pathological features associated with circulating tumor DNA content in real-world patients with metastatic prostate cancer.Semantic proximity Read ↗

Durable benefit from poly(ADP-ribose) polymerase inhibitors in metastatic prostate cancer in routine practice: biomarker associations and implications for optimal clinical next-generation sequencing testingSemantic proximity Read ↗

Deep whole-genome ctDNA chronology of treatment-resistant prostate cancer.Semantic proximity Read ↗

Circulating tumor DNA and tissue complementarily detect genomic alterations in metastatic hormone-sensitive prostate cancerSemantic proximity Read ↗

Cell-free DNA profiling of metastatic prostate cancer reveals microsatellite instability, structural rearrangements and clonal hematopoiesisSemantic proximity Read ↗

Prognostic Significance of Circulating Tumor DNA in Metastatic Prostate Cancer: A Systematic Review and Meta-Analysis.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.